{"id":6333,"date":"2026-02-27T10:38:43","date_gmt":"2026-02-27T07:38:43","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=6333"},"modified":"2026-02-27T11:52:51","modified_gmt":"2026-02-27T08:52:51","slug":"santhera-agamree-spain-reimbursement-duchenne-muscular-dystrophy","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/santhera-agamree-spain-reimbursement-duchenne-muscular-dystrophy\/","title":{"rendered":"Santhera, Duchenne Musk\u00fcler Distrofisi Tedavisi i\u00e7in AGAMREE (Vamorolone)&#039;nin \u0130spanya Ulusal Sa\u011fl\u0131k Sistemine Dahil Edilmesi ve Geri \u00d6demesinin Sa\u011flanmas\u0131 Teklifini Duyurdu"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Santhera Pharmaceuticals, \u0130spanya Bakanl\u0131klararas\u0131 \u0130la\u00e7 Fiyatlar\u0131 Komisyonu&#039;nun AGAMREE (vamorolone) ilac\u0131n\u0131 \u0130spanya Ulusal Sa\u011fl\u0131k Sistemi&#039;nin ila\u00e7 kapsam\u0131na dahil etmeyi ve b\u00f6ylece geri \u00f6demeye uygun hale getirmeyi \u00f6nerdi\u011fini duyurdu. Daha fazla bilgi edinin: <a href=\"https:\/\/dmdwarrior.com\/tr\/what-is-agamree-vamorolone-what-is-agamree-used-for\/\" target=\"_blank\" data-type=\"post\" data-id=\"2333\" rel=\"noreferrer noopener\">AGAMREE (Vamorolone) nedir?<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Bu t\u00fcr bir dahil edilmenin \u015fartlar\u0131, \u0130spanya Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 Eczac\u0131l\u0131k Genel M\u00fcd\u00fcrl\u00fc\u011f\u00fc taraf\u0131ndan \u00e7\u0131kar\u0131lacak bir kararname ile belirlenecektir.<\/strong> \u015eirket, s\u00f6z konusu karar tasla\u011f\u0131n\u0131 k\u0131sa s\u00fcre i\u00e7inde almay\u0131 bekliyor. \u015eirket tasla\u011f\u0131 kabul ettikten sonra, \u00fcr\u00fcn \u0130spanya&#039;daki Ulusal Sa\u011fl\u0131k Sistemi taraf\u0131ndan finanse edilen \u00fcr\u00fcnler veri taban\u0131na dahil edilecek. Bu s\u00fcrecin tipik zaman \u00e7izelgelerine uygun ilerlemesi durumunda, Santhera, \u00fcr\u00fcn\u00fc 2026 y\u0131l\u0131n\u0131n ikinci \u00e7eyre\u011finin ba\u015flar\u0131ndan itibaren \u0130spanya&#039;n\u0131n \u00e7e\u015fitli b\u00f6lgelerinde kullan\u0131ma sunmay\u0131 planl\u0131yor.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Agamree, Avrupa Komisyonu taraf\u0131ndan 4 ya\u015f ve \u00fczeri hastalarda Duchenne kas distrofisi tedavisinde kullan\u0131lmak \u00fczere onaylanm\u0131\u015f bir \u00fcr\u00fcnd\u00fcr.<\/strong> Duchenne kas distrofisi, kaslarda kademeli olarak g\u00fc\u00e7s\u00fczl\u00fc\u011fe ve fonksiyon kayb\u0131na neden olan genetik bir hastal\u0131kt\u0131r. AGAMREE, bug\u00fcne kadar \u0130spanya&#039;da 2024 y\u0131l\u0131n\u0131n ortalar\u0131ndan itibaren \u00fccretli, belirli hastalar\u0131 kapsayan bir program arac\u0131l\u0131\u011f\u0131yla kullan\u0131ma sunulmu\u015ftur.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Santhera CEO&#039;su Dario Eklund \u015funlar\u0131 s\u00f6yledi: &quot;\u0130spanya&#039;daki bu olumlu duyuru, Avrupa&#039;da ve k\u00fcresel olarak DMD hastalar\u0131 i\u00e7in AGAMREE&#039;ye eri\u015fimi geni\u015fletme misyonumuzda bir di\u011fer \u00f6nemli kilometre ta\u015f\u0131n\u0131 temsil ediyor. Bu, Almanya, Avusturya ve \u0130ngiltere&#039;deki ticari lansmanlar\u0131m\u0131z\u0131n ard\u0131ndan geliyor ve y\u0131l\u0131n ilk ve ikinci yar\u0131s\u0131nda bir dizi ek AB \u00fclkesinin de bunu takip etmesi bekleniyor.&quot;\u201c<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Devam\u0131n\u0131 oku<\/strong>:&nbsp;<a href=\"https:\/\/dmdwarrior.com\/tr\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Duchenne \u0130\u00e7in Klinik Ara\u015ft\u0131rmalar (T\u00fcm Ara\u015ft\u0131rmalar\u0131n Listesi)<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Santhera Pharmaceuticals announces that the Spanish Interministerial Commission on Prices of Medicines, has proposed to include AGAMREE (vamorolone), in the pharmaceutical coverage of the Spanish National Health System, making it eligible for reimbursement. Learn More: What is AGAMREE (Vamorolone) The conditions for such inclusion will be determined in a resolution by the Directorate-General of Pharmacy [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":6335,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[42,498,499,43],"class_list":["post-6333","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-agamree","tag-spanish-interministerial-commission","tag-vamorolone"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/6333","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=6333"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/6333\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/6335"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=6333"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=6333"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=6333"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}